This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Lab Study of MQX-503 in Treatment of Raynaud's

This study has been completed.
Information provided by:
MediQuest Therapeutics Identifier:
First received: November 13, 2005
Last updated: May 29, 2007
Last verified: May 2007

The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phenomenon, follwoing exposure to cold temperatures.

Blood flow is determined by scanning laser Doppler equipment and skin temperature is measured using attached thermistor probes. Following baseline measurements, the study gel is applied, the hand is placed in a cold chamber, and then blood flow and skin temperature are monitored for the next two hours.

Each patient will receive multiple doses on different days so that each can serve as his/her own control in interpreting the response.

Condition Intervention Phase
Raynaud Disease Raynaud Disease Secondary to Scleroderma Raynaud Secondary to Other Autoimmune Disease Drug: topical organogel with nitroglycerin Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s Phenomenon

Resource links provided by NLM:

Further study details as provided by MediQuest Therapeutics:

Primary Outcome Measures:
  • Differntial time for blood flow to return to baseline following cold exposure.

Secondary Outcome Measures:
  • Differential time for skin temperature to return to baseline following cold exposure.
  • Quantitative reduction or prevention in symptoms following cold exposure.

Estimated Enrollment: 36
Study Start Date: November 2004
Estimated Study Completion Date: September 2005

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of Raynaud's phenomenon
  • outpoatients
  • agree to apply gel as per protocol
  • willing to discontinue current vasodilator therapy
  • agree to stop other investigational medication for Raynaud's
  • negative pregnancy test is fertile females
  • able to give written informed consent and comply with study requirements

Exclusion Criteria:

  • current use of ay nitrate medication or medications that interact with nitroglycerin
  • patients with a known allergy to nitroglycerin or topical gel ingredients
  • patients with a history of migraine headaches
  • patients with unstable medical problems
  • patients with cognitive or language difficulties
  • patients with screening lab values more than 20% outside of normal
  • patients with open lesions at site of application
  • women of child-bearing potential who are unwilling to comply with contraceptive requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00253331

United States, Maryland
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224
United States, Washington
University of Washington Medical College
Seattle, Washington, United States, 98195
Sponsors and Collaborators
MediQuest Therapeutics
Principal Investigator: Laura K Hummers, MD Johns Hopkins University
Principal Investigator: Carin Dugowson, MD, MPH University of Washington Medical College
  More Information Identifier: NCT00253331     History of Changes
Other Study ID Numbers: MQT 03-001
Study First Received: November 13, 2005
Last Updated: May 29, 2007

Keywords provided by MediQuest Therapeutics:
systemic sclerosis
autoimmune disease

Additional relevant MeSH terms:
Raynaud Disease
Neoplasm Metastasis
Autoimmune Diseases
Neoplastic Processes
Pathologic Processes
Immune System Diseases
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases
Vasodilator Agents processed this record on September 21, 2017